February 24, 2021
Otsuka Pharmaceutical and Click Therapeutics have announced the launch of a new, fully remote clinical trial being conducted on Verily's Project Baseline platform.
Called the Mirai study, it will be measuring a digital therapeutics intervention's effectiveness in reducing symptoms of depression among adults who have a major depressive disorder (MDD) diagnosis and are on antidepressant monotherapy...
February 3, 2021
Highmark, a Blue Cross Blue Shield-affiliated health insurer, will expand access to Freespira's digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms.
In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from...
August 20, 2020
Picking through the scraps. Following the bankruptcy of 'digital pill' maker Proteus Digital Health, business partner and stakeholder Otsuka Pharmaceutical has been approved to purchase the digital health company's assets by a federal bankruptcy court judge, STAT reports.
Otsuka's bid was challenged by Novartis, two former Proteus executives and other investors, who argued that the agreed upon $...
July 9, 2020
Pharma giant Otsuka is rolling out a new kidney focused platform called NephU that provides online resources about nephrology conditions and a place for clinicians to collaborate and share information amongst themselves, and with patients.
Users will be able to tap into an online library of resources that include video, audio, webinars and podcasts. According to the site, the “community”...
January 14, 2020
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments.
The pharmaceutical company has now acquired the full license for Proteus’ mental health...
August 30, 2018
Otsuka Pharmaceuticals and Proteus Digital Health’s sensor-carrying pill Abilify MyCite is on its way to US patients thanks to a new collaboration agreement between Otsuka and Magellan Health. Announced this morning by the pharmaceutical company, the rollout will initially be limited to give Otsuka and Magellan a better idea of how best to deploy the technology at scale.
“We are eager for...
July 6, 2012
Proteus Biomedical's Raisin system
Intelligent medicine platform developer Proteus Biomedical has changed its name to Proteus Digital Health, to "better reflect" what the company does, Chief Product Officer David O'Reilly told MobiHealthNews in an email this week. Proteus also inked a deal with Japan-based Otsuka Pharmaceutical, which is known for its Abilify drug for schizophrenia and bipolar...